Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 1/2 3Phase NA 2Phase EARLY_PHASE1 2Phase 2/3 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Dermatologic 1

Conditions

Glioblastoma 2Melanoma 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Disulfiram × Clear all
NCT02715609 2025-04-10

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase 1/2 Completed
35 enrolled 16 charts
CNS

Glioblastoma

NCT02770378 2021-10-05

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

University of Ulm

Phase 1/2 Completed
10 enrolled
CNS

Glioblastoma

NCT00256230 2016-12-08

Disulfiram in Patients With Metastatic Melanoma

University of California, Irvine

Phase 1/2 Completed
7 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡